Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Cited by (461)

Items 101–200 of 461

1. N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains
   Apostolos Klinakis, Zoe Cournia, Theodoros N Rampias · 2021 · Computational and Structural Biotechnology Journal
2. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
   Franck Touret, Cécile Baronti, Hawa Sophia Bouzidi, Xavier Nicolas de Lamballerie · 2022 · Scientific Reports
3. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
   Jiandong Huo, Aiste Dijokaite-Guraliuc, Chang Liu, Daming Zhou, Helen Mary Ginn, Raksha Das, Piyada Supasa, Muneeswaran Selvaraj, Rungtiwa Nutalai, Aekkachai Tuekprakhon et al. · 2022 · Cell Reports
4. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
   Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds et al. · 2021 · Nature Immunology
5. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity
   Bo Meng, Rawlings P. Datir, Jinwook Choi, Stephen G. Baker, Gordon Dougan, Christoph Hess, Nathalie Kingston, Paul J. Lehner, Paul Lyons, Nicholas J. Matheson et al. · 2022 · Cell Reports
6. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
   Manon Ragonnet‐Cronin, Rungtiwa Nutalai, Jiandong Huo, Aiste Dijokaite-Guraliuc, Raksha Das, Aekkachai Tuekprakhon, Piyada Supasa, Chang Liu, Muneeswaran Selvaraj, Natalie Groves et al. · 2023 · Nature Communications
7. A Single Amino Acid at Residue 188 of the Hexon Protein Is Responsible for the Pathogenicity of the Emerging Novel Virus Fowl Adenovirus 4
   Yu Zhang, Aijing Liu, Yanan Wang, Hongyu Cui, Yulong Gao, Xiaole Qi, Changjun Liu, Yanping Zhang, Kai Li, Li Gao et al. · 2021 · Journal of Virology
8. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
   Fuxing Lou, Maochen Li, Zehan Pang, Lin Jiang, Lin Guan, Lili Tian, Jiaming Hu, Junfen Fan, Huahao Fan · 2021 · Frontiers in Immunology
9. Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern
   Jesse W. Wotring, Reid M. Fursmidt, Loren S. Ward, Jonathan Z. Sexton · 2022 · Journal of Dairy Science
10. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
    Bruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes dos Santos Fonseca, Luis Alberto Breda Mascarenhas, Leone Peter Correia da Silva Andrade, Vinícius Pinto Costa Rocha, Milena Botelho Pereira Soares, Peter Berglund, Malcolm S. Duthie, Steven G. Reed et al. · 2021 · Vaccines
11. An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants
    Trina Ekawati Tallei, Fatimawali Fatimawali, Afriza Yelnetty, Rinaldi Idroes, Diah Kusumawaty, Talha Bin Emran, Talha Z. Yesiloglu, Wolfgang Sippl, Shafi Mahmud, Taha Alqahtani et al. · 2021 · Frontiers in Pharmacology
12. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants
    Dibya Ghimire, Yang Han, Maolin Lu · 2022 · Viruses
13. An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
    Alejandro Pascual‐Iglesias, Javier Cantón, Ana Maria Ortega‐Prieto, Jose M. Jiménez-Guardeño, José Ángel Regla-Nava · 2021 · Pathogens
14. Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core
    Alexander J. Pak, Alvin Yu, Zunlong Ke, John A. G. Briggs, Gregory A. Voth · 2022 · Nature Communications
15. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance
    Lirong Cao, Jingzhi Lou, See Yeung Chan, Hong Zheng, Caiqi Liu, Shi Zhao, Qi Li, Chris Ka Pun Mok, Renee W. Y. Chan, Ka Chun Chong et al. · 2022 · Nature Medicine
16. The Natural Stilbenoid (–)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants
    Ian Tietjen, Joel Cassel, Emery T. Register, Xiang Yang Zhou, Troy E. Messick, Frederick Keeney, Lily D. Lu, Karren D. Beattie, Topul Rali, Pablo Tebas et al. · 2021 · Antimicrobial Agents and Chemotherapy
17. Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions
    Mary Hongying Cheng, James Krieger, Anupam Banerjee, Yufei Xiang, Burak Kaynak, Yi Shi, Moshe Arditi, İvet Bahar · 2022 · iScience
18. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status
    Sheila Lumley, Gillian Rodger, Bede Constantinides, Nicholas Sanderson, Kevin K Chau, Teresa L Street, Denise O’Donnell, Alison Howarth, Stephanie B. Hatch, Brian D. Marsden et al. · 2021 · medRxiv
19. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity
    Michihito Sasaki, Shinsuke Toba, Yukari Itakura, Herman M. Chambaro, Mai Kishimoto, Koshiro Tabata, Kittiya Intaruck, Kentaro Uemura, Takao Sanaki, Akihiko Sato et al. · 2021 · mBio
20. Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
    Rukmankesh Mehra, Kasper P. Kepp · 2021 · ACS Infectious Diseases
21. Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies
    Chengchao Ding, Jun He, Xiangyu Zhang, Chengcheng Jiang, Yong Chang Sun, Yuqing Zhang, Qingqing Chen, Hongliang He, Wenting Li, Jiajia Xie et al. · 2021 · Frontiers in Immunology
22. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
    Ane Ogbe, Matthew J. Pace, Mustapha Bittaye, Timothy Tipoe, Sandra Adele, Jasmini Alagaratnam, Parvinder K. Aley, M. Azim Ansari, Anna Bara, Samantha Broadhead et al. · 2022 · JCI Insight
23. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine
    Sonia Jangra, Jeffrey J. Landers, Raveen Rathnasinghe, Jessica J. O’Konek, Katarzyna W. Janczak, Marília Cascalho, Andrew A. Kennedy, Andrew W. Tai, James R. Baker, Michael Schotsaert et al. · 2021 · Frontiers in Immunology
24. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
    Pedro M. Folegatti, Daniel Jenkin, Susan Jane Morris, Sarah C. Gilbert, Denny Kim, James S. Robertson, Emily R. Smith, Emalee Martin, Marc Gurwith, Robert T. Chen · 2022 · Vaccine
25. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
    Adrian Rice, Mohit S. Verma, Annie Shin, Lise Zakin, Peter A. Sieling, Shiho Tanaka, Joseph P. Balint, Kyle Dinkins, Helty Adisetiyo, Brett Morimoto et al. · 2021 · Scientific Reports
26. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
    Mohd Zulkifli Salleh, Mohd Nor Norazmi, Zakuan Zainy Deris · 2022 · PeerJ
27. Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity
    Balamurugan Shanmugaraj, Narach Khorattanakulchai, Chalisa Panapitakkul, Ashwini Malla, Rawiwan Im‐Erbsin, Manutsanun Inthawong, Piyanate Sunyakumthorn, Taweewun Hunsawong, Chonticha Klungthong, Matthew C. Reed et al. · 2022 · Vaccine
28. An updated review of SARS‐CoV ‐2 detection methods in the context of a novel coronavirus pandemic
    Yuxuan Zhang, Zhiwei Huang, Jiajie Zhu, Chaonan Li, Zhongbiao Fang, Keda Chen, Yanjun Zhang · 2022 · Bioengineering & Translational Medicine
29. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
    Lei Peng, Yingxia Hu, Madeleine C. Mankowski, Ping Ren, Rita E. Chen, Jin Wei, Min Zhao, Tongqing Li, Therese N. Tripler, Lupeng Ye et al. · 2022 · Nature Communications
30. COVID-19: From emerging variants to vaccination
    Thilini Hemali Senevirathne, Demi Wekking, Joseph W. R. Swain, Cinzia Solinas, Pushpamali De Silva · 2023 · Cytokine & Growth Factor Reviews
31. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
    Aiste Dijokaite-Guraliuc, Raksha Das, Daming Zhou, Helen Mary Ginn, Chang Liu, Helen M. E. Duyvesteyn, Jiandong Huo, Rungtiwa Nutalai, Piyada Supasa, Muneeswaran Selvaraj et al. · 2023 · Cell Reports
32. Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency
    Ahmed L. Alaofi, Mudassar Shahid · 2021 · Biomolecules
33. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients
    Q. Yan, P. He, Xiaohan Huang, K. Luo, Yu-Di Zhang, Haisu Yi, Qian Wang, Feng Li, Rui-Tian Hou, Xiaodi Fan et al. · 2021 · Emerging Microbes and Infections
34. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern
    Lixiao Xing, Xinfeng Xu, Wei Xu, Zezhong Liu, Xin Shen, Jie Zhou, Ling Xu, Jing Pu, Chan Yang, Yuan Huang et al. · 2022 · Viruses
35. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
    Ester López, Ebene R. Haycroft, Amy Adair, Francesca L. Mordant, Matthew T. O’Neill, Phillip Pymm, Samuel J. Redmond, Wen Shi Lee, Nicholas A. Gherardin, Adam K. Wheatley et al. · 2021 · JCI Insight
36. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
    Kang Wang, Yunlong Cao, Yunjiao Zhou, Jiajing Wu, Zijing Jia, Yaling Hu, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu et al. · 2021 · medRxiv
37. The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
    Sandrine Mabekou Soh, Yeongjun Kim, Chanwoo Kim, Ui Soon Jang, Hye-Ra Lee · 2021 · The Journal of Microbiology
38. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
    Lu Lu, Allen Wing‐Ho Chu, Ruiqi Zhang, Wan-Mui Chan, Jonathan Daniel Ip, Hoi‐Wah Tsoi, Lin‐Lei Chen, Jian‐Piao Cai, David Christopher Lung, Anthony Raymond Tam et al. · 2021 · EBioMedicine
39. N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation
    Wenyang Zhou, Chang Xu, Pingping Wang, Meng Luo, Zhaochun Xu, Rui Cheng, Xiyun Jin, Yu Guo, Guangfu Xue, Liran Juan et al. · 2021 · Frontiers in Cell and Developmental Biology
40. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants
    Claudio Fenizia, Silvia Galbiati, Claudia Vanetti, Riccardo Vago, Mario Clerici, Carlo Tacchetti, Tiziana Daniele · 2022 · Microbiology Spectrum
41. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants
    Cong Sun, Yinfeng Kang, Yuan-Tao Liu, Xiang‐Wei Kong, Hui-Qin Xu, Dan Xiong, Chu Xie, Yihao Liu, Sui Peng, Guo‐Kai Feng et al. · 2022 · Signal Transduction and Targeted Therapy
42. Divergent trajectories of antiviral memory after SARS-CoV-2 infection
    Adriana Tomić, Donal Skelly, Ane Ogbe, Daniel O’Connor, Matthew J. Pace, Emily Adland, Frances Alexander, Mohammad Ali, Kirk Allott, M. Azim Ansari et al. · 2022 · Nature Communications
43. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
    Zezhong Liu, Wei Xu, Zhenguo Chen, Wangjun Fu, Wuqiang Zhan, Yidan Gao, Jie Zhou, Yunjiao Zhou, Jianbo Wu, Qian Wang et al. · 2021 · Protein & Cell
44. Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants
    Severino Jefferson Ribeiro da Silva, Suelen Cristina de Lima, Ronaldo Celerino da Silva, Alain Kohl, Lindomar Pena · 2022 · Frontiers in Medicine
45. Characterisation of B.1.1.7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2
    Samuel J. Dicken, Matthew J Murray, Lucy Thorne, Ann‐Kathrin Reuschl, Calum Forrest, Maaroothen Ganeshalingham, Luke Muir, Mphatso D. Kalemera, Machaela Palor, Laura E. McCoy et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
46. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
    Meiyu Wang, Li Zhang, Qianqian Li, Bo Wang, Ziteng Liang, Yeqing Sun, Jianhui Nie, Jiajing Wu, Xiao‐Dong Su, Xiaowang Qu et al. · 2021 · Emerging Microbes & Infections
47. Synthesis, Structural Characterizations, and Quantum Chemical Investigations on 1-(3-Methoxy-phenyl)-3-naphthalen-1-yl-propenone
    Prakashgouda G. Patil, Raveendra M. Melavanki, Shivaraj B. Radder, Raviraj A. Kusanur, Chidanandayya S. Hiremath, Ninganagouda R. Patil, Sudhir M. Hiremath · 2021 · ACS Omega
48. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
    Rafael Bayarri‐Olmos, Laust Bruun Johnsen, Manja Idorn, Line Sinnathamby Reinert, Anne Rosbjerg, Søren Vang, Cecilie Bo Hansen, Charlotte Helgstrand, Jais Rose Bjelke, Theresa Bak-Thomsen et al. · 2021 · eLife
49. SARS‐CoV‐2 omicron variant: Could it be another threat?
    Balamurugan Shanmugaraj, Ashwini Malla, Narach Khorattanakulchai, Waranyoo Phoolcharoen · 2021 · Journal of Medical Virology
50. The Immune Response to SARS-CoV-2 and Variants of Concern
    Elham Torbati, Kurt L. Krause, James E. Ussher · 2021 · Viruses
51. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
    Yi-Nan Zhang, Jennifer Paynter, Cindy Sou, Tatiana Fourfouris, Ying Wang, Ciril Abraham, Timothy Ngo, Yi Zhang, Linling He, Jiang Zhu · 2021 · Science Advances
52. Immune response against SARS-CoV-2 variants: the role of neutralization assays
    Alicja Chmielewska, Anna Czarnota, Krystyna Bieńkowska-Szewczyk, Katarzyna Grzyb · 2021 · npj Vaccines
53. The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
    Yao Jiang, Qian Yun Wu, Peipei Song, Chongge You · 2022 · Frontiers in Medicine
54. Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021
    Paola Stefanelli, Filippo Trentini, Giorgio Dirani, Valentina Marziano, Alessia Mammone, Piero Poletti, Carla Molina Grané, Mattia Manica, Martina Del Manso, Xanthi D. Andrianou et al. · 2022 · Eurosurveillance
55. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected
    Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, Sara Pierucci, Chiara Busti, Claudia Monari, Barbara Luciani Pasqua, Filippo Dragoni, Elisabetta Schiaroli, Maurizio Zazzi et al. · 2021 · Journal of Infection
56. Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis
    Kai Wang, Lin Wang, Mingzhe Li, Bing Xie, Lu He, Meiyu Wang, Rumin Zhang, Nianzong Hou, Yi Zhang, Fusen Jia · 2022 · Frontiers in Medicine
57. Advances in mRNA and other vaccines against MERS-CoV
    Wanbo Tai, Xiujuan Zhang, Yang Yang, Jiang Zhu, Lanying Du · 2021 · Translational research
58. SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility
    Mariana Valério, Luís Borges-Araújo, Manuel N. Melo, Diana Lousa, Cláudio M. Soares · 2022 · Frontiers in Medical Technology
59. Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences
    Randall J. Olsen, Paul A. Christensen, Scott Wesley Long, Sishir Subedi, Parsa Hodjat, Robert Olson, Marcus Nguyen, James J. Davis, Prasanti Yerramilli, Matthew Ojeda Saavedra et al. · 2021 · American Journal Of Pathology
60. Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
    Blake Marie Hauser, Maya Sangesland, Kerri St. Denis, Evan Christopher Lam, James Brett Case, Ian W. Windsor, Jared E. Feldman, Timothy M. Caradonna, Ty Kannegieter, Michael Diamond et al. · 2022 · Cell Reports
61. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
    Paulina Kapłonek, Yixiang Deng, Jessica Shih-Lu Lee, Heather Joy Zar, Dace Zavadska, Marina Johnson, Douglas A. Lauffenburger, David Goldblatt, Galit Alter · 2023 · Cell Reports Medicine
62. Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic
    Xue Li, Liying Zhang, Si Emma Chen, Weilong Ji, Chang Li, Linzhu Ren · 2021 · Infection Genetics and Evolution
63. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
    Shiqi Xu, Yifan Wang, Yanxing Wang, Chao Zhang, Hong Qin, Chenjian Gu, Rong Xu, Tingfeng Wang, Yong Ping Yang, Jinkai Zang et al. · 2021 · Emerging Microbes & Infections
64. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
    Chang Liu, Daming Zhou, Aiste Dijokaite-Guraliuc, Piyada Supasa, Helen M. E. Duyvesteyn, Helen Mary Ginn, Muneeswaran Selvaraj, Alexander J. Mentzer, Raksha Das, Thushan I. de Silva et al. · 2024 · Cell Reports Medicine
65. Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
    Aekkachai Tuekprakhon, Jiandong Huo, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen Mary Ginn, Muneeswaran Selvaraj, Chang Liu, Alexander J. Mentzer, Piyada Supasa et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
66. Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2
    Nicolas Castonguay, Wandong Zhang, Marc‐André Langlois · 2021 · Frontiers in Microbiology
67. Free energy perturbation calculations of mutation effects on SARS-CoV-2 RBD::ACE2 binding affinity
    Sergeeva, Alina P., Katsamba, Phinikoula S., Liao, Junzhuo, Sampson, Jared M., Bahna, Fabiana, Mannepalli, Seetha, Morano, Nicholas C., Shapiro, Lawrence, Friesner, Richard A., Honig, Barry · 2023 · Journal of Molecular Biology
68. High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
    Takuya Tada, Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Amber R. Cornelius, Ramin S. Herati, Mark J. Mulligan, Nathaniel Roy Landau · 2021 · Cell Reports
69. Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective
    Yinghan Chan, Sin Wi Ng, Sachin Kumar Singh, Monica Gulati, Gaurav Gupta, Sushil Kumar Chaudhary, Goh Bey Hing, Trudi Collet, Ronan J. MacLoughlin, Raimar Löbenberg et al. · 2021 · Life Sciences
70. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
    Yu Kaku, Takeo Kuwata, Hasan Md Zahid, Takao Hashiguchi, Takeshi Noda, Noriko Kuramoto, Shashwata Biswas, Kaho Matsumoto, Mikiko Shimizu, Yoko Kawanami et al. · 2021 · Cell Reports
71. VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes
    Qinglan Sun, Chang Shu, Wenyu Shi, Yingfeng Luo, Guomei Fan, Jingyi Nie, Yuhai Bi, Qihui Wang, Jianxun Qi, Jian Lü et al. · 2021 · Nucleic Acids Research
72. Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers
    Pragya Dhruv Yadav, Prasad Sarkale, Alpana Razdan, Nivedita Gupta, Dimpal A. Nyayanit, Rima Rakeshkumar Sahay, Varsha Atul Potdar, Deepak Y. Patil, Shreekant Baradkar, Abhinendra Kumar et al. · 2021 · Journal of Infection and Public Health
73. Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation
    Kazuki Watanabe, Chiduru Watanabe, T. Honma, Yu-Shi Tian, Y. Kawashima, N. Kawashita, T. Takagi, Kaori Fukuzawa · 2021 · Journal of Physical Chemistry Letters
74. Microsimulation based quantitative analysis of COVID-19 management strategies
    Istvan Zoltan Reguly, Dávid Csercsik, János Juhász, Kálmán Tornai, Zsófia Bujtár, Gergely Horváth, Bence Márk Keömley-Horváth, Tamás Kós, György Cserey, Kristóf Iván et al. · 2022 · PLoS Computational Biology
75. Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
    Lianlian Bian, Jianyang Liu, Fan Gao, Qiushuang Gao, Qian He, Qunying Mao, Xing Wu, Miao Xu, Zhenglun Liang · 2022 · Human Vaccines & Immunotherapeutics
76. A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
    Rui Wang, Chunyun Sun, Juan Ma, Chulin Yu, Desheng Kong, Meng Chen, Xuejie Liu, Dandan Zhao, Shuman Gao, Shuyuan Kou et al. · 2022 · Vaccines
77. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
    Nungruthai Suntronwong, Ritthideach Yorsaeng, Jiratchaya Puenpa, Chompoonut Auphimai, Thanunrat Thongmee, Preeyaporn Vichaiwattana, Sitthichai Kanokudom, Thaneeya Duangchinda, Warangkana Chantima, Pattarakul Pakchotanon et al. · 2022 · Vaccines
78. Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response
    Jernej Pušnik, Julia König, Karola Mai, Enrico Richter, Jasmin Zorn, Hannah Proksch, Bianca Schulte, Galit Alter, Hendrik Streeck · 2022 · Journal of Virology
79. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
    James Anthony Torchia, Alexander H. Tavares, Laura Stentoft Carstensen, D. W. Chen, Jessie Huang, Tianshu Xiao, Sonia Mukherjee, Patrick M. Reeves, Hua Tu, Ann E. Sluder et al. · 2022 · Science Advances
80. Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity
    Eduardo Olmedillas, Colin J. Mann, Wei-Wei Peng, Ying-Ting Wang, Ruben Diaz Avalos, Daniel H. Bedinger, Kristen M. Valentine, N. Shafee, S. Schendel, M. Yuan et al. · 2021 · bioRxiv
81. Dynamics of SARS-CoV-2 Alpha (B.1.1.7) variant spread: The wastewater surveillance approach
    Albert Carcereny, David García-Pedemonte, Adán Martínez-Velázquez, Josep Quer, Damir García‐Cehic, Josep Gregori, Andrés Antón, Cristina Andrés, Tomàs Pumarola, Carme Chacón-Villanueva et al. · 2022 · Environmental Research
82. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
    Eliott Lafon, Michael Jäger, Angelika Bauer, Markus Reindl, Rosa Bellmann‐Weiler, Doris Wilflingseder, Cornelia Lass‐Flörl, Wilfried Posch · 2022 · Journal of Allergy and Clinical Immunology
83. Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2
    Jun Lan, Peng Chen, Weiming Liu, Wenlin Ren, Linqi Zhang, Qiang Ding, Qi Zhang, Xinquan Wang, Jiwan Ge · 2022 · Structure
84. Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
    Nungruthai Suntronwong, Sitthichai Kanokudom, Chompoonut Auphimai, Suvichada Assawakosri, Thanunrat Thongmee, Preeyaporn Vichaiwattana, Thaneeya Duangchinda, Warangkana Chantima, Pattarakul Pakchotanon, Jira Chansaenroj et al. · 2022 · Journal of Medical Virology
85. The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
    Qiuli Chen, Jiawei Zhang, Peter Wang, Zuyong Zhang · 2022 · iScience
86. SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression
    Daniela Niemeyer, Saskia Stenzel, Talitha Veith, Simon Schroeder, Kirstin Friedmann, Friderike Weege, Jakob Trimpert, Julian Heinze, Anja M. Richter, Jenny Jansen et al. · 2022 · PLoS Biology
87. Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant
    Claude Kwe Yinda, Julia Rebecca Port, Trenton Bushmaker, Robert J. Fischer, Jonathan E. Schulz, Myndi G. Holbrook, Carl Shaia, Emmie de Wit, Neeltje van Doremalen, Vincent Jacobus Munster · 2021 · Emerging Microbes & Infections
88. Chitosan derivatives: A suggestive evaluation for novel inhibitor discovery against wild type and variants of SARS-CoV-2 virus
    Chandrima Modak, Anubhuti Jha, Nivya Sharma, Awanish Kumar · 2021 · International Journal of Biological Macromolecules
89. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
    Rafael Bayarri‐Olmos, Ida Jarlhelt, Laust Bruun Johnsen, Cecilie Bo Hansen, Charlotte Helgstrand, Jais Rose Bjelke, Finn Matthiesen, Susanne Dam Nielsen, Kasper Karmark Iversen, Sisse Rye Ostrowski et al. · 2021 · Frontiers in Immunology
90. Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
    Ramesh J. L. Kandimalla, Pratik Chakraborty, Jayalakshmi Vallamkondu, Anupama Chaudhary, Sonalinandini Samanta, P. Hemachandra Reddy, Vincenzo De Feo, Saikat Dewanjee · 2021 · Biomedicines
91. Antibody-mediated immunity to SARS-CoV-2 spike
    John M. Errico, Lucas J. Adams, Daved H. Fremont · 2022 · Advances in immunology
92. Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2
    Shi Zhao, Jingzhi Lou, Ka Chun Chong, Lirong Cao, Hong Zheng, Zigui Chen, Renee W. Y. Chan, Benny Chung-Ying Zee, Paul K.S. Chan, Maggie Haitian Wang · 2021 · Viruses
93. Effect of Prophylactic Use of Intranasal Oil Formulations in the Hamster Model of COVID-19
    Zaigham Abbas Rizvi, Manas Ranjan Tripathy, Nishant Sharma, Sandeep Goswami, Narayanam Srikanth, J.L.N. Sastry, Shailendra Mani, Milan Surjit, Amit Awasthi, Madhu Dikshit · 2021 · Frontiers in Pharmacology
94. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
    Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi et al. · 2021 · Microbiology Spectrum
95. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity
    Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Yumiko Saga, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka et al. · 2021 · Microbiology Spectrum
96. New nickel( ii ) Schiff base complexes as potential tools against SARS-CoV-2 Omicron target proteins: an in silico approach
    Sunil kumar V, Mukesh Choudhary · 2023 · New Journal of Chemistry
97. The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
    David Stuart, Chang Liu, Raksha Das, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen M. E. Duyvesteyn, Alexander J. Mentzer, Piyasa Supasa, Muneeswaran Selvaraj, Thomas G. Ritter et al. · 2024 · Nature Communications
98. Molecular Level Dissection of Critical Spike Mutations in SARS‐CoV‐2 Variants of Concern (VOCs): A Simplified Review
    Nilesh Joshi, Adish Tyagi, Sandeep Nigam · 2021 · ChemistrySelect
99. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
    Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Mengze Gan, Xiaosong Lin, Xionglin Fan · 2021 · Frontiers in Immunology
100. Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
     Benjamin Trinité, Edwards Pradenas, Sílvia Marfil, Carla Rovirosa, Víctor Urrea, Ferran Tarrés-Freixas, Raquel Ortiz, Jordi Rodon, Júlia Vergara‐Alert, Joaquím Segalés et al. · 2021 · Viruses